Codexis Inc (CDXS) - Total Assets
Based on the latest financial reports, Codexis Inc (CDXS) holds total assets worth $123.96 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Codexis Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Codexis Inc - Total Assets Trend (2006–2024)
This chart illustrates how Codexis Inc's total assets have evolved over time, based on quarterly financial data. See Codexis Inc (CDXS) shareholders funds for net asset value and shareholders' equity analysis.
Codexis Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Codexis Inc's total assets of $123.96 Million consist of 66.3% current assets and 33.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.9% |
| Accounts Receivable | $18.88 Million | 12.7% |
| Inventory | $1.80 Million | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $2.46 Million | 1.7% |
Asset Composition Trend (2006–2024)
This chart illustrates how Codexis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CDXS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Codexis Inc's current assets represent 66.3% of total assets in 2024, a decrease from 78.5% in 2006.
- Cash Position: Cash and equivalents constituted 12.9% of total assets in 2024, down from 69.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 8.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
Codexis Inc Competitors by Total Assets
Key competitors of Codexis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Codexis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.12 | 3.21 | 7.38 |
| Quick Ratio | 4.02 | 3.15 | 7.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $57.72 Million | $77.77 Million | $159.44 Million |
Codexis Inc - Advanced Valuation Insights
This section examines the relationship between Codexis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.88 |
| Latest Market Cap to Assets Ratio | 0.76 |
| Asset Growth Rate (YoY) | 9.1% |
| Total Assets | $149.01 Million |
| Market Capitalization | $112.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Codexis Inc's assets below their book value (0.76x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Codexis Inc's assets grew by 9.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Codexis Inc (2006–2024)
The table below shows the annual total assets of Codexis Inc from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $149.01 Million | +9.12% |
| 2023-12-31 | $136.56 Million | -45.46% |
| 2022-12-31 | $250.39 Million | +1.63% |
| 2021-12-31 | $246.38 Million | +11.16% |
| 2020-12-31 | $221.65 Million | +48.68% |
| 2019-12-31 | $149.07 Million | +90.43% |
| 2018-12-31 | $78.28 Million | +45.98% |
| 2017-12-31 | $53.62 Million | +50.43% |
| 2016-12-31 | $35.65 Million | -20.16% |
| 2015-12-31 | $44.65 Million | -7.22% |
| 2014-12-31 | $48.12 Million | -18.22% |
| 2013-12-31 | $58.84 Million | -41.14% |
| 2012-12-31 | $99.97 Million | -26.45% |
| 2011-12-31 | $135.92 Million | -3.81% |
| 2010-12-31 | $141.30 Million | +42.68% |
| 2009-12-31 | $99.04 Million | +39.72% |
| 2008-12-31 | $70.88 Million | -37.57% |
| 2007-12-31 | $113.54 Million | +143.34% |
| 2006-12-31 | $46.66 Million | -- |
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more